Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 16, 2018 - Issue 5
Submit an article Journal homepage
764
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Response to: ‘Letter to the Editor: “Management of multidrug-resistant Pseudomonas aeruginosa in the Intensive Care Unit: state of the art”’

Alberto Enrico MaraoloDepartment of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, ItalyCorrespondence[email protected]
View further author information
,
Marco CascellaDivision of Anesthesia, Department of Anesthesia and Pain Medicine, Istituto Nazionale Tumori – IRCCS – Fondazione G. Pascale, Naples, ItalyView further author information
,
Silvia CorcioneDepartment of Medical Sciences, University of Turin, Turin, ItalyView further author information
,
Arturo CuomoDivision of Anesthesia, Department of Anesthesia and Pain Medicine, Istituto Nazionale Tumori – IRCCS – Fondazione G. Pascale, Naples, ItalyView further author information
,
Salvatore NappaDepartment of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, ItalyView further author information
,
Guglielmo BorgiaDepartment of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, ItalyView further author information
,
Francesco Giuseppe De RosaDepartment of Medical Sciences, University of Turin, Turin, ItalyView further author information
&
Ivan GentileDepartment of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, ItalyView further author information
 show all
Pages 369-371 | Published online: 16 May 2018

References

  • Plant AJ, Dunn A, Porter RJ. Letter to the editor: ‘Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art’. Expert Rev Anti Infect Ther. 2018 May 4. doi: 10.1080/14787210.2018.1473079. [Epub ahead of print].
  • Maraolo AE, Cascella M, Corcione S, et al. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art. Expert Rev Anti Infect Ther. 2017;15:861–871.
  • Gentile I, Maraolo AE, Borgia G. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam? Expert Rev Anti Infect Ther. 2016;14:875–878.
  • Shortridge D, Pfaller MA, Castanheira M, et al. Antimicrobial activity of ceftolozane-tazobactam tested against enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013-2016) as part of the surveillance program: program to assess ceftolozane-tazobactam susceptibility. Microb Drug Resist. 2017. Epub ahead of print. DOI:10.1089/mdr.2017.0266.
  • Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74:31–51.
  • Giani T, Arena F, Pollini S, et al. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. J Antimicrob Chemother. 2017. Epub ahead of print. DOI:10.1093/jac/dkx453.
  • Shortridge D, Castanheira M, Pfaller MA, et al. Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from U.S. hospitals: report from the PACTS antimicrobial surveillance program, 2012 to 2015. Antimicrob Agents Chemother. 2017 Jun 27;61:e00465–17.
  • Pfaller MA, Shortridge D, Sader HS, et al. Ceftolozane-tazobactam activity against drug-resistant enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: report from an antimicrobial surveillance program (2013-2015). J Glob Antimicrob Resist. 2017;10:186–194.
  • Pfaller MA, Shortridge D, Sader HS, et al. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015). Braz J Infect Dis. 2017;21:627–637.
  • Van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis. 2016;63:234–241.
  • ClinicalTrial.gov. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (MK-7625A-008) (ASPECT-NP). [cited 2017 Dec 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02070757?term=ceftolozane&rank=5
  • Xiao AJ, Miller BW, Huntington JA, et al. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016;56:56–66.
  • Flynt LK, Veve MP, Samuel LP, et al. Comparison of etest to broth microdilution for testing of susceptibility of Pseudomonas aeruginosa to ceftolozane-tazobactam. J Clin Microbiol. 2016;55:334–335.
  • ClinicalTrial.gov. Plasma pharmacokinetics (PK) & lung penetration of ceftolozane/tazobactam in participants with pneumonia (MK-7625A-007). [cited 2017 Dec 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02387372?term=ceftolozane&rank=4
  • Gentile I, Buonomo AR, Maraolo AE, et al. Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy. J Antimicrob Chemother. 2017;72:2678–2679.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.